Melanoma

CME

Melanoma Great Debate: Targeted versus Complete Nodal Dissection following Neoadjuvant Therapy for Melanoma: Is it Time to Push Forward or Hold off on Continued De-escalation of Surgery?

Moderator(s)

• 

  Marc Moncrieff, MD FRCS(Plast.)

  Professor of Plastic & Reconstructive Surgery
  Norfolk & Norwich University Hospital
  Norwich, United Kingdom

  Disclosure(s): No financial relationships to disclose

Neoadjuvant immunotherapy has been increasingly adopted for the treatment of patients with clinically apparent stage 3 disease. As this becomes increasingly adopted, it is unclear if targeted lymph node removal, albeit potentially prognostic, is sufficient to manage the regional nodal basin. This debate will highlight the evidence for this approach and future directions in the field of neoadjuvant immunotherapy for the treatment of melanoma.

Presentations:

• 10:37am – 10:52am ET

  Pro/Affirmative
  

  Debater - Pro: Alexander C.J van Akkooi, MD, PhD (he/him/his) – Melanoma Institute Australia / University of Sydney, Faculty of Medicine and Health / Royal Prince Alfred Hospital, Department of Melanoma and Surgical Oncology
• 10:52am – 11:07am ET

  Con/Negative
  

  Debater - Con: Charlotte E. Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center
• 11:07am – 11:20am ET

  Questions and Discussion